RT Journal Article
T1 Usefulness of a Nanostructured Fibrin-Agarose Bone Substitute in a Model of Severely Critical Mandible Bone Defect
A1 Martin-Piedra, Miguel-Angel
A1 Girones-Camarasa, Belen
A1 Espana-Lopez, Antonio
A1 Fernandez-Valades Gamez, Ricardo
A1 Blanco-Elices, Cristina
A1 Garzon, Ingrid
A1 Alaminos, Miguel
A1 Fernandez-Valades, Ricardo
K1 bone
K1 tissue engineering
K1 fibrin-agarose
K1 mandible
K1 regeneration
K1 Stem-cells
K1 Regeneration
K1 Repair
AB Critical defects of the mandibular bone are very difficult to manage with currently available materials and technology. In the present work, we generated acellular and cellular substitutes for human bone by tissue engineering using nanostructured fibrin-agarose biomaterials, with and without adipose-tissue-derived mesenchymal stem cells differentiated to the osteogenic lineage using inductive media. Then, these substitutes were evaluated in an immunodeficient animal model of severely critical mandibular bone damage in order to assess the potential of the bioartificial tissues to enable bone regeneration. The results showed that the use of a cellular bone substitute was associated with a morpho-functional improvement of maxillofacial structures as compared to negative controls. Analysis of the defect site showed that none of the study groups fully succeeded in generating dense bone tissue at the regeneration area. However, the use of a cellular substitute was able to improve the density of the regenerated tissue (as determined via CT radiodensity) and form isolated islands of bone and cartilage. Histologically, the regenerated bone islands were comparable to control bone for alizarin red and versican staining, and superior to control bone for toluidine blue and osteocalcin in animals grafted with the cellular substitute. Although these results are preliminary, cellular fibrin-agarose bone substitutes show preliminary signs of usefulness in this animal model of severely critical mandibular bone defect.
PB Mdpi
YR 2021
FD 2021-11-01
LK https://hdl.handle.net/10668/26351
UL https://hdl.handle.net/10668/26351
LA en
DS RISalud
RD Apr 19, 2025